Condition: Idiopathic Pulmonary Fibrosis · Sponsor: Trevi Therapeutics
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
This description comes directly from the study's public registry record.
Paula Buckley · (203) 304-2499 · Paula.Buckley@trevitherapeutics.com
Always discuss trial participation with your own doctor first.
| Pulmonary Specialists of The Palm Beaches | Loxahatchee Groves, Florida, United States | Recruiting |
| Clinical Research and Associates, Inc. | Miami, Florida, United States | Recruiting |
| Clinical Research of Gastonia (CRG) | Gastonia, North Carolina, United States | Recruiting |
| El Paso Pulmonary Association, PA | El Paso, Texas, United States | Recruiting |
| Elevate Clinical Research | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07671911